Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan : vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
BACKGROUND: Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan.
METHODS: We conducted a multicenter test-negative case-control study. The study comprised individuals aged ≥16 visiting medical facilities with COVID-19-related signs or symptoms from 1 January to 26 June 2022, when Omicron BA.1 and BA.2 were dominant nationwide. We evaluated VE of primary and booster vaccination against symptomatic SARS-CoV-2 infections and relative VE of booster compared with primary.
RESULTS: We enrolled 7,931 episodes, including 3,055 test positive. The median age was 39, 48.0% were male, and 20.5% had underlying medical conditions. In individuals aged 16 to 64, VE of primary vaccination within 90 days was 35.6% (95% CI, 19.0-48.8%). After booster, VE increased to 68.7% (60.6-75.1%). In individuals aged ≥65, VE of primary and booster was 31.2% (-44.0-67.1%) and 76.5% (46.7-89.7%), respectively. Relative VE of booster compared with primary vaccination was 52.9% (41.0-62.5%) in individuals aged 16 to 64 and 65.9% (35.7-81.9%) in individuals aged ≥65.
CONCLUSIONS: During BA.1 and BA.2 epidemic in Japan, mRNA COVID-19 primary vaccination provided modest protection. Booster vaccination was necessary to protect against symptomatic infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Expert review of vaccines - 22(2023), 1 vom: 01. Jan., Seite 288-298 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maeda, Haruka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BA.1 |
|---|
| Anmerkungen: |
Date Completed 21.03.2023 Date Revised 27.03.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/14760584.2023.2188950 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353891355 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353891355 | ||
| 003 | DE-627 | ||
| 005 | 20231226061040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14760584.2023.2188950 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353891355 | ||
| 035 | |a (NLM)36883371 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maeda, Haruka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan |b vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2023 | ||
| 500 | |a Date Revised 27.03.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Evaluating COVID-19 vaccine effectiveness (VE) domestically is crucial for assessing and determining national vaccination policy. This study aimed to evaluate VE of mRNA COVID-19 vaccines in Japan | ||
| 520 | |a METHODS: We conducted a multicenter test-negative case-control study. The study comprised individuals aged ≥16 visiting medical facilities with COVID-19-related signs or symptoms from 1 January to 26 June 2022, when Omicron BA.1 and BA.2 were dominant nationwide. We evaluated VE of primary and booster vaccination against symptomatic SARS-CoV-2 infections and relative VE of booster compared with primary | ||
| 520 | |a RESULTS: We enrolled 7,931 episodes, including 3,055 test positive. The median age was 39, 48.0% were male, and 20.5% had underlying medical conditions. In individuals aged 16 to 64, VE of primary vaccination within 90 days was 35.6% (95% CI, 19.0-48.8%). After booster, VE increased to 68.7% (60.6-75.1%). In individuals aged ≥65, VE of primary and booster was 31.2% (-44.0-67.1%) and 76.5% (46.7-89.7%), respectively. Relative VE of booster compared with primary vaccination was 52.9% (41.0-62.5%) in individuals aged 16 to 64 and 65.9% (35.7-81.9%) in individuals aged ≥65 | ||
| 520 | |a CONCLUSIONS: During BA.1 and BA.2 epidemic in Japan, mRNA COVID-19 primary vaccination provided modest protection. Booster vaccination was necessary to protect against symptomatic infections | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a BA.1 | |
| 650 | 4 | |a BA.2 | |
| 650 | 4 | |a COVID19 | |
| 650 | 4 | |a Japan | |
| 650 | 4 | |a SARSCoV2 | |
| 650 | 4 | |a omicron | |
| 650 | 4 | |a vaccine effectiveness | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Saito, Nobuo |e verfasserin |4 aut | |
| 700 | 1 | |a Igarashi, Ataru |e verfasserin |4 aut | |
| 700 | 1 | |a Ishida, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Terada, Mayumi |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Takayasu |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Hideko |e verfasserin |4 aut | |
| 700 | 1 | |a Kamura, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Motohashi, Iori |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Yuya |e verfasserin |4 aut | |
| 700 | 1 | |a Komino, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Arai, Hiromi |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwamitsu, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Akuzawa, Nobuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Sando, Eiichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Morikawa, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Imura, Haruki |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Hayakawa, Tomoichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Teshigahara, Osamu |e verfasserin |4 aut | |
| 700 | 1 | |a Ohara, Yasuji |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Motoi |e verfasserin |4 aut | |
| 700 | 1 | |a Morimoto, Konosuke |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of vaccines |d 2002 |g 22(2023), 1 vom: 01. Jan., Seite 288-298 |w (DE-627)NLM126545200 |x 1744-8395 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:288-298 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14760584.2023.2188950 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 1 |b 01 |c 01 |h 288-298 | ||